Interferon-Combination Strategies for the Treatment of Chronic Hepatitis C

Andrew Aronsohn; Donald Jensen

doi:10.1055/s-0034-1371008

Seminars in Liver Disease, Table of Contents

Semin Liver Dis 2014; 34(01): 030-036
DOI: 10.1055/s-0034-1371008

Thieme Medical Publishers 333 Seventh Avenue, New York, NY 10001, USA.

Interferon-Combination Strategies for the Treatment of Chronic Hepatitis C

Authors

Andrew Aronsohn

¹Center for Liver Disease, Section of Gastroenterology, Hepatology and Nutrition, University of Chicago Medical Center, Chicago, Illinois
Donald Jensen

¹Center for Liver Disease, Section of Gastroenterology, Hepatology and Nutrition, University of Chicago Medical Center, Chicago, Illinois

Abstract

Direct acting antiviral agents have revolutionized hepatitis C (HCV) therapy. Many agents that are either currently available or undergoing investigation offer higher rates of sustained virologic response, reduced toxicity and shorter duration of therapy when compared to traditional treatment consisting of pegylated interferon and ribavirin. Although interferon free therapy may be a preferred option, some patients may still require an interferon based regimen to ensure efficacy. In this review, we discuss therapeutic strategies which utilize various combinations of protease inhibitors, NS5A inhibitors, nucleotide polymerase inhibitors and non-nucleoside polymerase inhibitors along with pegylated interferon in the treatment of chronic HCV.

Keywords

hepatitis C - hepatitis C therapy - direct-acting antiviral agents

Full Text

References

References
1 Jacobson IM, McHutchison JG, Dusheiko G , et al; ADVANCE Study Team. Telaprevir for previously untreated chronic hepatitis C virus infection. N Engl J Med 2011; 364 (25) 2405-2416
2 Poordad F, McCone Jr J, Bacon BR , et al; SPRINT-2 Investigators. Boceprevir for untreated chronic HCV genotype 1 infection. N Engl J Med 2011; 364 (13) 1195-1206
3 Di Bisceglie A, Kuo A, Rustgi V, Sulkowski M. Virological outcomes and adherence to treatment algorithms in a longitudinal study of patients with chronic hepatitis C treated with boceprevir or telaprevir in the U.S. (HCV-TARGET). Paper presented at: AASLD The Liver Meeting; November 1–5, 2013; Washington, DC
4 Brass V, Berke JM, Montserret R, Blum HE, Penin F, Moradpour D. Structural determinants for membrane association and dynamic organization of the hepatitis C virus NS3-4A complex. Proc Natl Acad Sci U S A 2008; 105 (38) 14545-14550
5 Loo YM, Owen DM, Li K , et al. Viral and therapeutic control of IFN-beta promoter stimulator 1 during hepatitis C virus infection. Proc Natl Acad Sci U S A 2006; 103 (15) 6001-6006
6 Clark VC, Peter JA, Nelson DR. New therapeutic strategies in HCV: second-generation protease inhibitors. Liver Int 2013; 33 (Suppl. 01) 80-84
7 Jacobson I, Dore G, Foster G, Fried M. Simeprevir (TMC435) with peginterferon/ribavirin for chronic hCV genotype 1 infection in treatment-naïve patients: results from QUEST-1, a Phase III trial. Paper presented at: The 48th Annual Meeting of the European Association for Study of the Liver Amsterdam; April 24–28, 2013; Amsterdam, The Netherlands
8 Olysio. Available at: http:www:olysio.com . Accessed February 9, 2014
9 Manns M, Marcellin P, Poordad F, Addonso de Araujo E. Simeprevir (TMC435) with peginterferon-α2a or -α2b and ribavirin in treatment-naïve HCV genotype 1 patients: QUEST-2, a randomised phase III trial. Paper presented at: The 48th Annual Meeting of the European Association for Study of the Liver Amsterdam; April 24–28, 2013; Amsterdam, The Netherlands
10 Zeuzem S, Berg T, Gane E , et al. Simeprevir increases rate of sustained virologic response among treatment-experienced patients with HCV genotype-1 infection: a Phase IIb trial. Gastroenterology 2014; 146 (2) 430-, e6
11 Summa V, Ludmerer SW, McCauley JA , et al. MK-5172, a selective inhibitor of hepatitis C virus NS3/4a protease with broad activity across genotypes and resistant variants. Antimicrob Agents Chemother 2012; 56 (8) 4161-4167
12 Manns M, Vierling J, Bacon B, Marcellin P. High sustained viral response of MK-5172 with pegylated interferon alfa-2b and ribavirin in HCV genotype 1 treatment-naive non-cirrhotic patients. Paper presented at: The 48th Annual Meeting of the European Association for Study of the Liver Amsterdam; April 24–28, 2013; Amsterdam, The Netherlands
13 Bronowicki JP, Pol S, Thuluvath PJ , et al. Randomized study of asunaprevir plus pegylated interferon-. α and ribavirin for previously untreated genotype 1 chronic hepatitis C. Antivir Ther 2013; 18 (7) 885-893
14 Bronowicki JP, Ratziu V, Gadano A, Thuluvath PJ. Asunaprevir with peginterferon-alfa and ribavirin in treatment-naive patients with genotype-1 or -4 chronic hepatitis C: SVR24 results from a randomized phase 2b study (AI447–016). Paper presented at: The 48th Annual Meeting of the European Association for Study of the Liver Amsterdam; April 24–28, 2013; Amsterdam, The Netherlands
15 Sulkowski MS, Asselah T, Lalezari J , et al. Faldaprevir combined with pegylated interferon alfa-2a and ribavirin in treatment-naïve patients with chronic genotype 1 HCV: SILEN-C1 trial. Hepatology 2013; 57 (6) 2143-2154
16 Sulkowski MS, Bourlière M, Bronowicki JP , et al. Faldaprevir combined with peginterferon alfa-2a and ribavirin in chronic hepatitis C virus genotype-1 patients with prior nonresponse: SILEN-C2 trial. Hepatology 2013; 57 (6) 2155-2163
17 Jensen D, Asselah TD . D., Foster GR. A pooled analysis of two randomized, double-blind placebo-controlled Phase III trials (STARTVerso1&2) of faldaprevir plus pegylated interferon alfa-2a and ribavirin in treatment-naïve patients with chronic hepatitis C genotype-1 infection. Paper presented at: AASLD The Liver Meeting; November 1–5, 2013; Washington, DC
18 Jacobson I, Asselah T, Ferenci P, Foster G. STARTVerso3: A randomized, double-blind, placebo-controlled Phase III trial of faldaprevir in combination with pegylated interferon alfa-2a and ribavirin in treatment-experienced patients with chronic hepatitis C genotype-1 infection. Paper presented at: AASLD The Liver Meeting; November 1–5, 2013; Washington, DC
19 Rockstroh J, Nelson M, Soriano V, Arasteh K. STARTVerso 4 Phase III trial of faldaprevir plus peg interferon alfa-2a and ribavirin (PR) in patients with HIV and HCV genotype 1 coinfection: end of treatment response. Paper presented at: AASLD The Liver Meeting; November 1–5, 2013; Washington, DC
20 Lee C. Daclatasvir: potential role in hepatitis C. Drug Des Devel Ther 2013; 7: 1223-1233
21 Gao M, Nettles RE, Belema M , et al. Chemical genetics strategy identifies an HCV NS5A inhibitor with a potent clinical effect. Nature 2010; 465 (7294) 96-100
22 Dore G, Lawitz E, Hezode C, Shafran SD. Daclatasvir combined with Peginterferon Alfa 2a Alfa-and Ribavirin for 12 or 16 Weeks in patients with hepatitis C virus genotype 2 or 3 infection: COMMAND GT 2/3 study. Paper presented at: The 48th Annual Meeting of the European Association for Study of the Liver Amsterdam; April 24–28, 2013; Amsterdam, The Netherlands
23 Hezode C, Hirschfield GM, Ghesquiere W, Sievert W. Daclatasvir, an NS5A replication complex inhibitor, combined with peginterferon alfa-2a and ribavirin in treatment-naive HCV-genotype 1 or 4 patients: phase 2b COMMAND-1 SVR12 results. Paper presented at: AASLD The Liver Meeting; November 9–13, 2012; Boston, MA
24 Au JS, Pockros PJ. Novel therapeutic approaches for hepatitis C. Clin Pharmacol Ther 2013; 95 (1) 78-88
25 Lawitz E, Rodriquez-Torres M, Rustgi V, Hassanein T. Safety and antiviral activity of ANA598 in combination with pegylated interferon α2a plus ribavirin in treatment-naïve genotype-1 chronic HCV patients. Paper presented at: The 48th Annual Meeting of the European Association for Study of the Liver Amsterdam; April 24–28, 2013; Amsterdam, The Netherlands
26 Available at: A study of setrobuvir in combination with Pegasys (peginterferon alfa-2a) and Copegus (ribavirin) in patients with genotype 1 chronic hepatitis C. Available at: www.clinicaltrials.gov . Accessed December 27, 2013
27 Zeuzem S, Soriano V, Asselah T , et al. Faldaprevir and deleobuvir for HCV genotype 1 infection. N Engl J Med 2013; 369 (7) 630-639
28 Larrey D, Lohse AW, de Ledinghen V , et al. Rapid and strong antiviral activity of the non-nucleosidic NS5B polymerase inhibitor BI 207127 in combination with peginterferon alfa 2a and ribavirin. J Hepatol 2012; 57 (1) 39-46
29 Kowdley KV, Lawitz E, Crespo I , et al. Sofosbuvir with pegylated interferon alfa-2a and ribavirin for treatment-naive patients with hepatitis C genotype-1 infection (ATOMIC): an open-label, randomised, multicentre phase 2 trial. Lancet 2013; 381 (9883) 2100-2107
30 Lawitz E, Lalezari JP, Hassanein T , et al. Sofosbuvir in combination with peginterferon alfa-2a and ribavirin for non-cirrhotic, treatment-naive patients with genotypes 1, 2, and 3 hepatitis C infection: a randomised, double-blind, phase 2 trial. Lancet Infect Dis 2013; 13 (5) 401-408
31 Lawitz E, Mangia A, Wyles D , et al. Sofosbuvir for previously untreated chronic hepatitis C infection. N Engl J Med 2013; 368 (20) 1878-1887
32 Wedemeyer H, Jensen D, Herring Jr R , et al; PROPEL Investigators. PROPEL: a randomized trial of mericitabine plus peginterferon alpha-2a/ribavirin therapy in treatment-naïve HCV genotype 1/4 patients. Hepatology 2013; 58 (2) 524-537
33 Pockros PJ, Jensen D, Tsai N , et al; JUMP-C Investigators. JUMP-C: a randomized trial of mericitabine plus pegylated interferon alpha-2a/ribavirin for 24 weeks in treatment-naïve HCV genotype 1/4 patients. Hepatology 2013; 58 (2) 514-523
34 Feld J, Jacobson I, Jensen D, Foster G. Up to 100% SVR4 rates with ritonavir-boosted danoprevir (DNVr), mericitabine and ribavirin with or without peginterferon alfa-2a (40KD) in HCV genotype 1-infected partial and null responders: results from the MATTERHORN study. Paper presented at: AASLD The Liver Meeting; November 9–13, 2012; Boston, MA
35 ClinicalTrials.gov. A study of mericitabine in combination with telaprevir and Pegasys/Copegus in patients with chronic hepatitis C. Available at: http://clinicaltrials.gov/ct2/show/NCT01482390?term=mericitabine&rank=1 . Accessed February 9, 2014
36 ClinicalTrials.gov. A study of mericitabine in combination with boceprevir and Pegasys/Copegus in patients with chronic hepatitis C. Available at: http://clinicaltrials.gov/ct2/show/NCT01482403?term=mericitabine&rank=2 . Accessed February 9, 2014
37 Lok AS, Gardiner DF, Lawitz E , et al. Preliminary study of two antiviral agents for hepatitis C genotype 1. N Engl J Med 2012; 366 (3) 216-224
38 Lok AS, Hezode C, Lawitz E, Gardiner DF. Sustained virologic response in chronic HCV genotype (GT) 1-infected null responders with combination of daclatasvir (DCV; NS5A inhibitor) and asunaprevir (ASV; NS3 Inhibitor) with or without peginterferon alfa-2a/ribavirin (PEG/RBV). Paper presented at: AASLD The Liver Meeting; November 9–13, 2012; Boston, MA
39 Gane E, Di Bisceglie A, Sulkowski M, Jacobson I. VX-222/telaprevir in combination with peginterferon-alfa-2a and ribavirin in treatment-naïve genotype 1 HCV patients treated for 12 weeks: ZENITH study, SVR12 interim analysis. Paper presented at: The 22st Conference of the Asian Pacific Association for the Study of the Liver APASL February 16–19, 2012; Taipei, Taiwan
40 Zeuzem S, Buggisch P, Agarwal K , et al. The protease inhibitor, GS-9256, and non-nucleoside polymerase inhibitor tegobuvir alone, with ribavirin, or pegylated interferon plus ribavirin in hepatitis C. Hepatology 2012; 55 (3) 749-758
41 Pol S, Jablkowski M, Trenkle J, Kanwar B. Antiviral efficacy of the once daily NS3 protease inhibitor GS-9451, the non-nucleoside NS5B inhibitor tegobuvir (GS-9190), and pegylated interferon + ribavirin in treatment-naïve patients with genotype 1 hepatitis C infection. Paper presented at: The 48th Annual Meeting of the European Association for Study of the Liver Amsterdam; April 24–28, 2013; Amsterdam, The Netherlands